This is the second time the company has cut down prices of Zepbound on LillyDirect. Eli Lilly said it was making the weight ...

Eli Lilly and Co. is cutting the price for introductory doses of its weight-loss drug Zepbound again, as competition heats up ...

New WHO guidance calls for a worldwide obesity treatment “ecosystem” to ensure that GLP-1 weight-loss drugs are used fairly ...

Lilly's Zepbound price cuts ranged from $50 to $100, depending on the dosage, for consumers who pay cash via the drugmaker's ...

A promising obesity and diabetes drug stumbles in Alzheimer's trials, rattling markets. Did investors overreact, or is this a ...

In the early November announcement of its agreement with the government, Lilly pledged to reduce the self-pay price of ...

The share price of Danish pharmaceutical giant Novo Nordisk (NYSE: NVO) hit a four-year low Monday, falling below $44 a share in early trading, a level the stock hasn't seen since July 2021. What's ...

Novo Nordisk (NVO) remains a strong buy in the weight loss/diabetes market despite challenges. Read here for an investment ...

Novo Nordisk’s closest rival is Eli Lilly, whose GLP-1 drugs have also posted strong demand. A softer read on IRA discounts ...

In two studies, semaglutide failed to slow decline in thousands of people with early stages of Alzheimer's disease.

By Bhanvi Satija and Maggie Fick LONDON (Reuters) -Novo Nordisk shares rose 5% on Wednesday after analysts said negotiated ...